DWTXHealthcare · BiotechnologyThe 2 Wall Street analysts covering Dogwood Therapeutics, Inc. hold a median 12-month price target of $15 — +1239.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 21 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Dogwood Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (91): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (8): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on DWTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +1239.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 May 2026 | HC Wainwright & Co. | Reiterates | Buy | $12 |
| 27 Apr 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Feb 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 Jan 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 Sept 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 23 Apr 2025 | HC Wainwright & Co. | Upgrade | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
DWTX appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 22 Oct 2026, Dogwood Therapeutics, Inc. returned −79.7% against +15.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 71% of US stocks
Cheaper than 81% of US stocks
Cheaper than 69% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 22% of US stocks
Higher than 19% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Dogwood Therapeutics, Inc. has a market value of $39.1M and an enterprise value of $29.6M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$36.0M.
Diluted earnings per share, trailing twelve months: $−8.95.
Free cash flow in the twelve months to 30 June 2026: −$15.1M.
Trailing P/E: 0.5×; forward P/E: −0.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Dogwood Therapeutics, Inc. employs 8 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Dogwood Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Dogwood Therapeutics announced that management will participate in the 2026 Maxim Growth Summit, scheduled for October 12–14 in New York City.
Why it matters — DWTX watchers may note the company's upcoming participation in an investor and industry conference.
Dogwood Therapeutics announced completion of patient enrollment in its ongoing Halneuron Phase 2b Chemotherapy Induced Neuropathic Pain trial, with 239 patients enrolled, meeting the upper end of the planned enrollment target range. Topline data are expected in November 2026.
Why it matters — A DWTX watcher would care because completion of enrollment at the target level moves the Halneuron Phase 2b CINP trial a step closer to topline results, a key clinical milestone for the company's pain program.
Dogwood Therapeutics, Inc. (DWTX) discussed its Halneuron program and pipeline advances for chemotherapy-induced neuropathic pain during a transcript of the discussion. The item covers the company's progress on this treatment candidate.
Why it matters — A DWTX watcher would care because the discussion provides an update on the company's Halneuron pipeline for chemotherapy-induced neuropathic pain.
Dogwood Therapeutics announced that its Phase 2b study of Halneuron, an investigational treatment for chemotherapy-induced neuropathic pain, has enrolled more than 230 patients. The company expects to report top-line data from the trial later this fall.
Why it matters — The upcoming Phase 2b top-line data readout for Halneuron represents a significant clinical milestone for Dogwood Therapeutics that could determine the treatment's future development prospects.
Dogwood Therapeutics announced it will host a virtual key opinion leader (KOL) event on September 1, 2026, to discuss Halneuron for the treatment of chemotherapy-induced neuropathic pain (CINP). The event will feature Dr. J. Mark Joyce, Iain D. Dukes, and Dr. Jerry Evarts alongside company management to cover the unmet need and current treatment landscape for CINP.
Why it matters — The KOL event gives DWTX watchers an opportunity to hear expert perspectives on the unmet need and treatment landscape for CINP, providing additional context around the company's Halneuron development program.
The 2 Wall Street analysts covering Dogwood Therapeutics, Inc. have a median 12-month price target of $15, with estimates ranging from $12 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering Dogwood Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Dogwood Therapeutics, Inc. 42 out of 100 across roughly 4,600 US stocks as at 21 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 21 Oct 2026, Dogwood Therapeutics, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (91 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +1239.3% from the last close, and Ticker Nerd's factor model ranks Dogwood Therapeutics, Inc. 42 out of 100 as at 21 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Dogwood Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DWTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $15 over the next 12 months.
Dogwood Therapeutics, Inc. returned -79.7% over the 12 months to 22 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Dogwood Therapeutics Inc. is a development-stage biopharmaceutical company focused on advancing medicines for pain and neuropathy.
The most recent item we track (GlobeNewsWire, 6 Oct 2026): "Dogwood to Participate in the 2026 Maxim Growth Summit". Dogwood Therapeutics announced that management will participate in the 2026 Maxim Growth Summit, scheduled for October 12–14 in New York City.
Dogwood Therapeutics Inc. is a development-stage biopharmaceutical company focused on advancing medicines for pain and neuropathy. The company’s current pipeline centers on non-opioid therapies, including Halneuron®, a voltage-gated sodium channel modulator being developed for neuropathic pain and other pain conditions, and SP16, a cell-signaling-based program aimed at neuropathy and nerve damage. Dogwood Therapeutics also works on antiviral combination therapies designed for illnesses linked to virus-triggered immune responses, including pain and fatigue-related disorders. Based in Alpharetta, Georgia, Dogwood Therapeutics operates as a single-segment company with an emphasis on clinical development, preclinical research, and targeted treatment approaches for cancer-related pain, neuropathic disorders, and related conditions.
CEO Mr. Gregory Duncan · 8 employees · United States · https://dwtx.com
